ChEBI: Fezolinetant is a triazolopyrazine that is 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine substituted by 3-methyl-1,2,4-thiadiazol-5-yl, 4-fluorobenzoyl and methyl groups at positions 3, 7, and 8R, respectively. It is a prescription medicine used to reduce moderate to severe vasomotor symptoms due to menopause. It has a role as a neurokinin-3 receptor antagonist. It is a member of monofluorobenzenes, a triazolopyrazine, a member of thiadiazoles, a member of benzamides and a tertiary carboxamide.
Fezolinetant is an oral non-hormonal therapy that is an NK3R antagonist. It works by binding to and blocking the activity of NK3 receptors, which play a role in the regulation of body temperature in the brain.
The common side effects of Fezolinetant include abdominal pain, diarrhoea, insomnia, back pain, hot flushes and elevated liver transaminases.
